Movement Alert｜Tempus AI Rises 5.28% in Regular Trading, FDA Approval of xT CDx Platform and New AI Launch Continue to Drive Momentum

Market Focus06-04

On June 4, Tempus AI rose 5.28% in regular trading, trading at $52.095/share, with trading volume of $163 million.

On the news front, Tempus AI recently received FDA approval for its tumor-only xT CDx next-generation sequencing platform for comprehensive genomic profiling of solid tumors. This milestone makes Tempus the first laboratory with FDA companion diagnostic approval for both tumor-only and tumor-normal genomic profiling. The company expects the approval to deliver an estimated $200 increase in average selling price starting in 2027, enabling migration of its entire DNA-based solid tumor product portfolio to the newly approved platform.

Additionally, the company introduced Lens, its next-generation agentic AI platform designed for oncology drug development, helping teams design better clinical trials and target patient subgroups. Tempus also presented new results on its multimodal tumor foundation model at the ASCO annual meeting, reinforcing its positioning at the intersection of AI and precision medicine.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1123236212?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-04 22:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123236212","market":"us","top_or_hot":-1,"title":"Movement Alert｜Tempus AI Rises 5.28% in Regular Trading, FDA Approval of xT CDx Platform and New AI Launch Continue to Drive Momentum","media":"Market Focus","content":"<p><p>On June 4, Tempus AI rose 5.28% in regular trading, trading at $52.095/share, with trading volume of $163 million.</p><p>On the news front, Tempus AI recently received FDA approval for its tumor-only xT CDx next-generation sequencing platform for comprehensive genomic profiling of solid tumors. This milestone makes Tempus the first laboratory with FDA companion diagnostic approval for both tumor-only and tumor-normal genomic profiling. The company expects the approval to deliver an estimated $200 increase in average selling price starting in 2027, enabling migration of its entire DNA-based solid tumor product portfolio to the newly approved platform.</p><p>Additionally, the company introduced Lens, its next-generation agentic AI platform designed for oncology drug development, helping teams design better clinical trials and target patient subgroups. Tempus also presented new results on its multimodal tumor foundation model at the ASCO annual meeting, reinforcing its positioning at the intersection of AI and precision medicine.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Tempus AI Rises 5.28% in Regular Trading, FDA Approval of xT CDx Platform and New AI Launch Continue to Drive Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Tempus AI Rises 5.28% in Regular Trading, FDA Approval of xT CDx Platform and New AI Launch Continue to Drive Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-04 22:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 4, Tempus AI rose 5.28% in regular trading, trading at $52.095/share, with trading volume of $163 million.</p><p>On the news front, Tempus AI recently received FDA approval for its tumor-only xT CDx next-generation sequencing platform for comprehensive genomic profiling of solid tumors. This milestone makes Tempus the first laboratory with FDA companion diagnostic approval for both tumor-only and tumor-normal genomic profiling. The company expects the approval to deliver an estimated $200 increase in average selling price starting in 2027, enabling migration of its entire DNA-based solid tumor product portfolio to the newly approved platform.</p><p>Additionally, the company introduced Lens, its next-generation agentic AI platform designed for oncology drug development, helping teams design better clinical trials and target patient subgroups. Tempus also presented new results on its multimodal tumor foundation model at the ASCO annual meeting, reinforcing its positioning at the intersection of AI and precision medicine.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEM","symbol_name":"Tempus AI","start_time":0,"source_url":"","article_id":"1123236212","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123236212","pubTimestamp":1780583793,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 4, Tempus AI rose 5.28% in regular trading, trading at $52.095/share, with trading volume of $163 million.On the news front, Tempus AI recently received FDA approval for its tumor-only xT CDx...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEM":"Tempus AI"},"translate_title":"动感快讯|腾邦AI常规交易涨5.28%FDA批准xT CDx平台和新AI上市继续推动势头","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEM":1},"content_text":"On June 4, Tempus AI rose 5.28% in regular trading, trading at $52.095/share, with trading volume of $163 million.On the news front, Tempus AI recently received FDA approval for its tumor-only xT CDx next-generation sequencing platform for comprehensive genomic profiling of solid tumors. This milestone makes Tempus the first laboratory with FDA companion diagnostic approval for both tumor-only and tumor-normal genomic profiling. The company expects the approval to deliver an estimated $200 increase in average selling price starting in 2027, enabling migration of its entire DNA-based solid tumor product portfolio to the newly approved platform.Additionally, the company introduced Lens, its next-generation agentic AI platform designed for oncology drug development, helping teams design better clinical trials and target patient subgroups. Tempus also presented new results on its multimodal tumor foundation model at the ASCO annual meeting, reinforcing its positioning at the intersection of AI and precision medicine.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1123236212","isCrawlerRequest":true}